Clinical trial NCT00965861: SCRI Tissue Testing Registry
Official title: SCRI Tissue Testing Registry
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Melanoma
Myelodysplastic Syndrome
Multiple Myeloma
Lymphoma
Keywords: Tissue Registry
Tissue Collection
Unknown Primary
Breast
Lung
Gastrointestinal
Bone Marrow Transplant
Chronic Lymphocytic Leukemia
Central Nervous System
Head and Neck
Melanoma
Myelodysplastic syndrome
Multiple Myeloma
Lymphoma
Gynecologic
Genitourinary
Refractory Malignancy
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
First posted: 2009-08-26
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date.

Brief summary: Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

Detailed description: Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients allowing the use of their tumor tissue sample(s) for testing/analysis at a future date. Future testing may include assays for newly identified markers of potential prognostic and/or therapeutic value. These markers may be specific to an individual cancer type, or they may be present more generally in cancer and/or other conditions.

This study will consist of a registry of patients who have agreed to allow their tissue sample(s) (even those taken prior to their participation in an SCRI-sponsored trial) to be used by the SCRI Oncology Research Consortium at some point in the future for testing and analysis of expression analysis and/or analysis of tumor markers. The registry will be contained in an electronic database, and will be sorted by disease indication. (Note: Patients will not be asked to return at a future date and have tissue samples collected; rather, SCRI will have the authorization to obtain pre-existing samples).

Eligibility criteria: Inclusion Criteria:

* Patients must be \>= 18 years of age.
* Patients must be able to provide written informed consent.

Exclusion Criteria:

* Not Applicable

Primary outcomes:
measure: To establish an electronic registry to store information from patients who have provided their consent allowing use of their tissue sample(s) for future testing.
timeFrame: 120 months
measure: To perform testing on the tissue samples to learn more about specific types of cancer and/or other diseases
timeFrame: 120 months
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
Study officials:
affiliation: SCRI Development Innovations, LLC
name: Howard Burris, M.D.
role: STUDY_CHAIR
References: